Vaccination against pseudorabies with glycoprotein gI+ or glycoprotein gI vaccine

J. Vandeputte From the Rhône Mérieux, Laboratoire IFFA, 254, rue Marcel Mérieux, F-69342 LYON Cedex 07.

Search for other papers by J. Vandeputte in
Current site
Google Scholar
PubMed
Close
 DVM
,
G. Chappuis From the Rhône Mérieux, Laboratoire IFFA, 254, rue Marcel Mérieux, F-69342 LYON Cedex 07.

Search for other papers by G. Chappuis in
Current site
Google Scholar
PubMed
Close
 DVM
,
D. Fargeaud From the Rhône Mérieux, Laboratoire IFFA, 254, rue Marcel Mérieux, F-69342 LYON Cedex 07.

Search for other papers by D. Fargeaud in
Current site
Google Scholar
PubMed
Close
 DSC
,
P. Précausta From the Rhône Mérieux, Laboratoire IFFA, 254, rue Marcel Mérieux, F-69342 LYON Cedex 07.

Search for other papers by P. Précausta in
Current site
Google Scholar
PubMed
Close
 DVM
,
F. Guillemin From the Rhône Mérieux, Laboratoire IFFA, 254, rue Marcel Mérieux, F-69342 LYON Cedex 07.

Search for other papers by F. Guillemin in
Current site
Google Scholar
PubMed
Close
 DVM
,
A. Brun From the Rhône Mérieux, Laboratoire IFFA, 254, rue Marcel Mérieux, F-69342 LYON Cedex 07.

Search for other papers by A. Brun in
Current site
Google Scholar
PubMed
Close
 DVM
,
Ph. Desmettre From the Rhône Mérieux, Laboratoire IFFA, 254, rue Marcel Mérieux, F-69342 LYON Cedex 07.

Search for other papers by Ph. Desmettre in
Current site
Google Scholar
PubMed
Close
 DVM
, and
C. Stellmann From the Rhône Mérieux, Laboratoire IFFA, 254, rue Marcel Mérieux, F-69342 LYON Cedex 07.

Search for other papers by C. Stellmann in
Current site
Google Scholar
PubMed
Close
 DVM

Click on author name to view affiliation information

SUMMARY

Subunit pseudorabies vaccines that contained only purified glycoproteins of either of 2 strains of pseudorabies virus (prv) were prepared and subsequently tested for safety and efficacy. The strains of virus used for vaccine production differed in at least 2 properties. One strain (Kojnok) was virulent for pigs and was believed to code for the entire complement of viral glycoproteins. The other (Kaplan) was a deletion mutant that was unable to code for structural viral glycoproteins gI and gp63. Purified glycoproteins were dispersed in an oil-in-water emulsion and were administered im to pigs.

Both vaccines were found to be safe and effective immunogens. Neither caused any local or general reactions, as verified by examination of the injection site (local safety) and by vaccination of pregnant sows in prv-infected and noninfected herds.

Sows vaccinated with the gI+ or gI- vaccine protected their pigs at levels of 93 and 92%, respectively, against a severe challenge exposure that killed 98% of pigs born from nonvaccinated sows. Vaccinated pigs were tested for active immunity by intranasal challenge exposure with the NIA 3 strain. Protection was quantitated by measuring the relative daily weight difference, expressed in percent per day, between vaccinated and control pigs during the first week after challenge exposure (ΔG7); the estimated differences were 2.25 and 2.13% for gI+ and gI vaccines, respectively.

The absence of gI and gp63 did not affect the efficacy of this type of subunit glycoprotein vaccines. In pigs that were challenge-exposed intranasally 3 months after 1 injection with the gI vaccine, the duration of viral excretion was highly reduced, compared with that in control pigs.

SUMMARY

Subunit pseudorabies vaccines that contained only purified glycoproteins of either of 2 strains of pseudorabies virus (prv) were prepared and subsequently tested for safety and efficacy. The strains of virus used for vaccine production differed in at least 2 properties. One strain (Kojnok) was virulent for pigs and was believed to code for the entire complement of viral glycoproteins. The other (Kaplan) was a deletion mutant that was unable to code for structural viral glycoproteins gI and gp63. Purified glycoproteins were dispersed in an oil-in-water emulsion and were administered im to pigs.

Both vaccines were found to be safe and effective immunogens. Neither caused any local or general reactions, as verified by examination of the injection site (local safety) and by vaccination of pregnant sows in prv-infected and noninfected herds.

Sows vaccinated with the gI+ or gI- vaccine protected their pigs at levels of 93 and 92%, respectively, against a severe challenge exposure that killed 98% of pigs born from nonvaccinated sows. Vaccinated pigs were tested for active immunity by intranasal challenge exposure with the NIA 3 strain. Protection was quantitated by measuring the relative daily weight difference, expressed in percent per day, between vaccinated and control pigs during the first week after challenge exposure (ΔG7); the estimated differences were 2.25 and 2.13% for gI+ and gI vaccines, respectively.

The absence of gI and gp63 did not affect the efficacy of this type of subunit glycoprotein vaccines. In pigs that were challenge-exposed intranasally 3 months after 1 injection with the gI vaccine, the duration of viral excretion was highly reduced, compared with that in control pigs.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 58 58 16
PDF Downloads 18 18 0
Advertisement